# Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

> **NCT06627751** · PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 28 (estimated)

## Conditions studied

- Extramedullary Disease in Multiple Myeloma
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Mezigdomide
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Computed Tomography Assisted Biopsy
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT06627751
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06627751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06627751, "Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06627751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*